‘I shouldn’t be here right now, and yet, I graduated from U of T’: The inspiring story of DLSPH’s first Doctor of Public Health graduate - Dalla Lana School of Public Health

AtlanticNova ScotiaNew BrunswickPrince Edward Island Newfoundland and LabradorCalgaryLethbridgeKitchenerGuelphNorthern OntarioSudburyNorth BaySault Ste. MarieTimminsOttawaKingstonBrockvillePembrokeReginaYorktonSaskatoonPrince AlbertTorontoWatchWeatherPeelHamiltonDurhamYorkHaltonNiagaraQueen's ParkToronto City HallIn PicturesVancouverVancouver IslandCanadaLocal SpotlightRoyal FamilyPoliticsNanosPower PlayQuestion PeriodFederal Election 2025WorldMideast ConflictRussia-Ukraine WarWatchLatestCaptured on CameraPoliticsLifestyleConsumerHealthExplainedEntertainmentTechnologyDeception DecodedAutosEnvironmentBusinessInflationReal EstateAutos

Pakistani health officials have confirmed the seventh polio case of 2026 for Pakistan from Karachi East District in Sindh. The affected child is a six-month-old male from Union Council Jamali Colony of Karachi East. The last case from Karachi was reported in December 2024. Of this year’s 7 reported cases, five are from Khyber Pakhtunkhwa (four from southern KP alone) and two are from Sindh. Despite an overall decline in wild poliovirus transmission, Karachi has continued to report environmental detections throughout the year, indicating that ongoing transmission remains a real threat for children. Subscribe to Outbreak News TV on YouTubeIn 2026, Pakistan has already implemented four large-scale polio campaigns, protecting more than 45 million children multiple times, alongside smaller targeted oral and injectable vaccination campaigns in high-risk areas. In September, a subnational campaign protected over 29.3 million children across the country, while the next vaccination round is scheduled from November 2-8 to protect nearly 24 million in 97 districts, including all districts of Karachi.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion on October 15, recommending an extension of indication for AstraZeneca’s H5N1 pandemic influenza vaccine.1 The extension removes the upper age limit from the vaccine’s current indication, which covers children and adolescents aged 12 months to younger than 18 years.2,3Pandemic influenza vaccine H5N1 AstraZeneca (pandemic influenza vaccine [H5N1] [live attenuated, nasal]; AstraZeneca) is an intranasal pandemic preparedness vaccine with conditional EU authorization since 2016.³ It is intended for use only after an official pandemic declaration and in line with official recommendations.¹What the CHMP Indication Extension Means AstraZeneca applied to remove the upper age limit based on efficacy and safety data already submitted in the original marketing authorization application, according to the CHMP agenda.² The revised indication covers active immunisation against influenza in an officially declared pandemic situation, used in accordance with official recommendations.¹ Adults would become eligible alongside children aged 12 months and older once the change